JMC14
JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity[1].
Product Specifications
CAS Number
2256080-83-6
UNSPSC
12352005
Target
C-Fms; PI3K
Related Pathways
PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
OC(C1CCN(CC1)CC2=C(N3N=C(N=C(C3=C2)N4CCOCC4)C5=CN=C(C=C5C(F)(F)F)N)C)(C)C
Molecular Formula
C26H34F3N7O2
Molecular Weight
533.59
References & Citations
[1]Zhang X, et al. JMC14: a novel dual PI3Kδ/CSF1R inhibitor with potent antitumor activity in hematological and solid tumors. Acta Pharmacol Sin. 2025 May 19.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PI3Kα; PI3Kβ; PI3Kγ
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
